Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Inflammatory Bowel Diseases

Free Subscription 20.10.2025 1 Aliment Pharmacol Ther 1 Am J Gastroenterol 2 BMC Gastroenterol 2 Clin Gastroenterol Hepatol 1 Dig Dis 3 Dig Dis Sci 1 Gastroenterol Hepatol 3 Gastroenterology 10 Inflamm Bowel Dis 1 J Clin Gastroenterol 8 J Crohns Colitis 2 Lancet Gastroenterol Hepatol 2 PLoS One 1 Scand J Gastroenterol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. TANG CZ, Delau OR, Katz S, Axelrad JE, et al
   Mild Endoscopic Disease Activity Is Associated With Adverse Outcomes Among Older Adults With Inflammatory Bowel Disease.
   Aliment Pharmacol Ther. 2025 Oct 15. doi: 10.1111/apt.70414.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

2. GHONEIM S, Choe H, Boneschansker L, Sachdeva K, et al
   Delayed Remission With Advanced Therapies Is Not Associated With Worse One-Year Outcomes In Inflammatory Bowel Disease.
   Am J Gastroenterol. 2025 Oct 13. doi: 10.14309/ajg.0000000000003795.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

3. GAO Y, Zhang Y, Jiang P
   Population stratified differences between ATG16L1 rs2241880 polymorphism with Crohn's disease risk: a systematic review and meta-analysis.
   BMC Gastroenterol. 2025;25:735.
   PubMed         Abstract available
   
   
4. LIU X, Yan Y, Yi J, Luo D, et al
   Ustekinumab trough concentrations predict clinical remission in perianal fistulizing crohn's disease: a real-world retrospective cohort study.
   BMC Gastroenterol. 2025;25:718.
   PubMed         Abstract available
   
   

   
   Clin Gastroenterol Hepatol

5. LOUIS E, Sebastian S, Siegmund B, Bossuyt P, et al
   Long-term safety of vedolizumab in patients with ulcerative colitis/Crohn's disease: A prospective observational study.
   Clin Gastroenterol Hepatol. 2025 Oct 13:S1542-3565(25)00891.
   PubMed         Abstract available
   
   
6. ANDRADE P, Mascarenhas M, Mendes F, Rosa B, et al
   AI-ASSISTED CAPSULE ENDOSCOPY FOR DETECTION OF ULCERS AND EROSIONS IN CROHN'S DISEASE: A MULTICENTER VALIDATION STUDY.
   Clin Gastroenterol Hepatol. 2025 Oct 9:S1542-3565(25)00861.
   PubMed         Abstract available
   
   

   
   Dig Dis

7. DOUKAS PG, Doukas SG, Broder A
   Effectiveness and Safety of Fecal Microbiota Transplantation for Ulcerative Colitis Treatment: A Systematic Review and Meta-Analysis.
   Dig Dis. 2025 Oct 10:1-22. doi: 10.1159/000548568.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

8. WU Z, Sun X, Li B, Xie Z, et al
   Shared Biomarkers LCN2 and CXCL11 for Ulcerative Colitis and Colon Cancer: Bioinformatics Analysis and Diagnostic Model Construction.
   Dig Dis Sci. 2025 Oct 14. doi: 10.1007/s10620-025-09443.
   PubMed         Abstract available
   
   
9. ZHANG P, Xu S, Li N, Yu C, et al
   Faecalibacterium prausnitzii Ameliorates DSS-Induced Colitis via Modulating Bile Acid Metabolism and Regulating FXR Signaling.
   Dig Dis Sci. 2025 Jul 5. doi: 10.1007/s10620-025-09176.
   PubMed         Abstract available
   
   
10. SEVIM R, Erhan S, Matur E
    MicroRNAs as Key Modulators of Intestinal Barrier Function: Pattern Recognition Receptors, Epithelial Junctional Complexes, and Therapeutic Approaches.
    Dig Dis Sci. 2025;70:3206-3228.
    PubMed         Abstract available
    
    

    
    Gastroenterol Hepatol

11. MADERO L, Baston I, Brunet-Mas E, Calafat M, et al
    TUBERCULOSIS AND INFLAMMATORY BOWEL DISEASE.
    Gastroenterol Hepatol. 2025 Oct 14:502587. doi: 10.1016/j.gastrohep.2025.502587.
    PubMed         Abstract available
    
    

    
    Gastroenterology

12. LIU J, Shi Y, Yang Y
    Reevaluating the GRAVITI Trial of Subcutaneous Guselkumab for Crohn's Disease.
    Gastroenterology. 2025 Oct 10:S0016-5085(25)06109.
    PubMed        
    
    
13. XU J, Gao Y, Zhang Y
    Subcutaneous IL-23 Blockade as a Patient-Centered Strategy in Crohn's Disease.
    Gastroenterology. 2025 Oct 10:S0016-5085(25)06111.
    PubMed        
    
    
14. WANG H, Xue K, Kong Y, Shen X, et al
    GRAVITI Study on Guselkumab's Efficacy and Safety for Moderate to Severe Crohn's Disease.
    Gastroenterology. 2025 Oct 10:S0016-5085(25)06110.
    PubMed        
    
    

    
    Inflamm Bowel Dis

15. 
    Correction to: Controlled Hookworm Infection for Medication-free Maintenance in Patients with Ulcerative Colitis: A Pilot, Double-blind, Randomized Control Trial.
    Inflamm Bowel Dis. 2025 Oct 11:izaf235. doi: 10.1093.
    PubMed        
    
    
16. TORRES J, Moss A
    Introduction to the IBD Journal Supplement: "Prevention of IBD: Forecasting and Forestalling Inflammatory Bowel Disease Onset".
    Inflamm Bowel Dis. 2025;31.
    PubMed         Abstract available
    
    
17. GOETGEBUER RL, Ungaro RC, Feagan BG, Jairath V, et al
    How Should an IBD Prevention Trial Be Designed?
    Inflamm Bowel Dis. 2025;31.
    PubMed         Abstract available
    
    
18. RIBEIRO-MOURAO F, Agrawal M, Torres J, Peter I, et al
    Intervention(s) in the Early-Life Period to Modulate Inflammatory Bowel Disease Risk: What Could Be the Impact?
    Inflamm Bowel Dis. 2025;31.
    PubMed         Abstract available
    
    
19. KUGATHASAN S, Fiocchi C
    Towards IBD Prediction and Prevention: The Contribution of Genetics and Genomics.
    Inflamm Bowel Dis. 2025;31.
    PubMed         Abstract available
    
    
20. TURPIN W, Kalili H, Halfvarson J, Croitoru K, et al
    IBD Prediction Is Possible, but How Far Are We from Implementing It?
    Inflamm Bowel Dis. 2025;31.
    PubMed         Abstract available
    
    
21. LIU Y, Sha S, Ran Q, Shi H, et al
    Response to Letter to the Editor regarding "The Correlation between Fecal Amino Acids, Colonic Mucosal Taste Receptors, and Clinical Features and Indicators of Ulcerative Colitis: A Multicenter Exploratory Study".
    Inflamm Bowel Dis. 2025 Oct 13:izaf233. doi: 10.1093.
    PubMed        
    
    
22. YANAI H, Achler T, Ben-Tov A, Sharar Fischler T, et al
    Incidence of Ocular Manifestation After Adult-Onset Inflammatory Bowel Disease: A 20-Year Population-Based Cohort Study.
    Inflamm Bowel Dis. 2025 Oct 15:izaf213. doi: 10.1093.
    PubMed         Abstract available
    
    
23. KEETHA RAO N, Ghodous S, Gurram A, Khorasani M, et al
    Prevalence and Associated Factors of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease: An Updated Global Systematic Review and Meta-Analysis of over 1.5 Million Individuals.
    Inflamm Bowel Dis. 2025 Oct 17:izaf226. doi: 10.1093.
    PubMed         Abstract available
    
    
24. KHAN N, Sundararajan R, Patel D, Patel M, et al
    Comparative Risk of Serious Infections Associated With Treatment of Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Oct 16:izaf218. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Clin Gastroenterol

25. VASUDEVAN J, Larson D, Damianos J, Shori C, et al
    Fiber Intake in Inflammatory Bowel Disease: Impact of Disease Activity and Predictors of High Fiber Intake.
    J Clin Gastroenterol. 2025 Oct 14. doi: 10.1097/MCG.0000000000002258.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

26. RADIA C, Danso Y, Ritchie S, Hale M, et al
    Is 2nd JAKi treatment for UC worth the effort? A retrospective, multi-centre UK study.
    J Crohns Colitis. 2025;19:jjaf154.
    PubMed         Abstract available
    
    
27. NI L, Peng X, Huang Y, Zhu Y, et al
    Assessing intestinal fibrosis using an endoscopic photoacoustic-ultrasound balloon catheter in rabbits and a human subject.
    J Crohns Colitis. 2025;19:jjaf155.
    PubMed         Abstract available
    
    
28. CHKOLNAIA Z, Reinisch W, Uzzan M
    Modulating checkpoint molecules in inflammatory bowel diseases as a new therapeutic strategy: a narrative review.
    J Crohns Colitis. 2025;19:jjaf160.
    PubMed         Abstract available
    
    
29. SAMAAN MA, Cunningham G, Lim SH, Dawson P, et al
    Fecal loss of vedolizumab is associated with ulcerative colitis severity, lower serum vedolizumab levels, and rates of clinical response: results from the FAVOUR study.
    J Crohns Colitis. 2025;19:jjaf159.
    PubMed         Abstract available
    
    
30. VEYSSIERE M, Hammoudi N, Le Bourhis L, Hassid D, et al
    Blood proteomic signatures associated with disease activity in inflammatory bowel diseases.
    J Crohns Colitis. 2025;19:jjaf162.
    PubMed         Abstract available
    
    
31. 
    Correction to: Spatial immune profiling of Crohn's disease fistula carcinomas-defining a distinct cancer subtype.
    J Crohns Colitis. 2025;19:jjaf171.
    PubMed        
    
    
32. MACALUSO FS, Fries W, Viola A, Cappello M, et al
    Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study
    J Crohns Colitis. 2025 Oct 13:jjaf175. doi: 10.1093.
    PubMed         Abstract available
    
    
33. BATTAT R, Sangiorgi B, Linggi B, Gui X, et al
    Spatial transcriptomics reveals unique inflammatory signatures across all anatomic locations in post-operative crohn's disease.
    J Crohns Colitis. 2025 Oct 15:jjaf180. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Lancet Gastroenterol Hepatol

34. LI YIM AYF, Levin E, de Jonge WJ, Henneman P, et al
    Peripheral blood DNA methylation signatures to predict treatment response in Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:973-974.
    PubMed        
    
    
35. LI H, Zeng J, Zhang L, Guo Q, et al
    Peripheral blood DNA methylation signatures to predict treatment response in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:972-973.
    PubMed        
    
    

    
    PLoS One

36. SHEN P, Xiong H, Luo QH, Ding YF, et al
    Investigating the common genetic basis between inflammatory bowel disease and metabolic syndrome through genomic structural equation modeling.
    PLoS One. 2025;20:e0334456.
    PubMed         Abstract available
    
    
37. ALEM M, Abtahi Froushani SM, Hajighahramani N, Hosseini-Asl S, et al
    Immuno-informatics voyage through molecular mimicry of Heat Shock Proteins: Potential IBD immunopathogenesis.
    PLoS One. 2025;20:e0333618.
    PubMed         Abstract available
    
    

    
    Scand J Gastroenterol

38. CARLSEN A, Steinsbo O, Kvaloy JT, Aabakken L, et al
    Optimizing serum adalimumab levels in maintenance therapy via proactive therapeutic drug monitoring improves markers of disease activity in Crohn's disease.
    Scand J Gastroenterol. 2025 Oct 17:1-12. doi: 10.1080/00365521.2025.2573725.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.